Cancer-testing company ImpriMed raises $10 million Series A2 bridge round
It tests drug sensitivity on living patient cancer cells and targets FDA clearance by the first quarter of 2027.
ImpriMed Issuer · LB Investment Lead investor · NAVER D2SF Investor · Samsung Securities Investor · Alois Ventures Investor · BonAngels Investor · Han River Partners Investor